ArticleCureus2017
Valproate-Induced Hyperammonemic Encephalopathy.
Article in Cureus, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Valproate-induced hyperammonemic encephalopathy after aneurysm clipping surgery: a case report with literature review.Frontiers in medicine · 2026Article
- What drives hyperammonemic encephalopathy in AED users: monotherapy risks or polypharmacy perils?Frontiers in pharmacology · 2025Article
- Article
- Unusual case of sodium valproate-induced hyperammonaemia encephalopathy.BMJ case reports · 2023Article
- Article
- Effects of Low- and High-Dose Valproic Acid and Lamotrigine on the Heart in Female Rats.Cardiovascular toxicology · 2022Article
- The effect of sodium benzoate, L-carnitine, and phenylacetate on valproate-induced hyperammonemia in Male Wistar rats.International journal of physiology, pathophysiology and pharmacology · 2022Article
- Elucidating the Potential Side Effects of Current Anti-Seizure Drugs for Epilepsy.Current neuropharmacology · 2021Review
- Article
- Valproate-induced hyperammonemic encephalopathy: a case report.Journal of medical case reports · 2020Article
- Propionate and Alzheimer's Disease.Frontiers in aging neuroscience · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Valproate is the best choice drug for a variety of medical conditions. As with any other drug, it has adverse effects, and it is important to emphasize the possibility of those adverse effects to prevent complications. We present the case history of a 44-year-old male with valproate-induced hyperammonemic encephalopathy, despite having normal liver function tests. This case includes a detailed literature review of this rare adverse event. In the light of this case report, we illustrate the importance of checking ammonia levels in all psychiatric patients receiving valproate as a treatment who present with new onset neurological symptoms or altered mental status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.